Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 FAP 2286 - 3B Pharmaceuticals/Novartis

Next Previous
Drug Profile

Lutetium-177 FAP 2286 - 3B Pharmaceuticals/Novartis

Alternative Names: 177Lu-FAP-2286

Latest Information Update: 27 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3B Pharmaceuticals; Novartis
  • Developer Novartis
  • Class Antineoplastics; Peptides; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action DNA damage stimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 25 Mar 2025 Ankara University plans the phase II FAUNUS trial for Bladder cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable), in June 2025 (NCT06880757)
  • 13 Sep 2024 Efficacy and adverse event data from the phase I/II Lumiere trial presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 14 Apr 2023 Pharmacodynamics and pharmacokinetics data from a preclinical studies in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top